Tsingke Biotechnology
Tsingke Biotech (Пекин, Китай) — компания синтетической биологии: полный цикл «чтения», редактирования и синтеза генов с ИИ-проектированием молекул, собственными реагентами, синтезаторами и автоматикой. Три платформы: высокопроизводительный скрининг олигонуклеотидов, поиск и производство антител, конструирование и скрининг микробных штаммов — для биофармацевтики, промышленной биотехнологии, …
Профиль
Beijing Tsingke Biotech Co., Ltd. is a China-based biotechnology company that provides integrated DNA and RNA synthesis services, molecular reagents, and synthetic biology tools for research and industrial applications. Its core platform, the Gene Factory, utilizes proprietary automated synthesizers, in-house reagents, and AI-driven workflows to support services including oligonucleotide synthesis, gene synthesis (up to 200 kb), protein and antibody expression, and GMP-compliant nucleic acid production for therapeutics.
Founded in 2002 and incorporated in 2017, the company is headquartered in Beijing E-Town, China. It is a venture-backed firm that converted to a joint-stock company in 2023 and successfully listed on the National Equities Exchange and Quotations (NEEQ) in January 2026. As of 2026, the company remains active, employing over 1,200 people and serving more than 300,000 customers globally. Recent developments include the launch of a redesigned global website, strategic partnerships with firms like iGeneTech, and the expansion of its small nucleic acid therapeutic capabilities.
Sources#
- Who We Are - Beijing Tsingke Biotech Co., Ltd.
- Tsingke: DNA & RNA Synthesis Biotech Services
- Tsingke Biotech 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- Tsingke Biotech — Whiteford Research Biobase
- Integrated DNA & RNA Synthesis Facility | Tsingke Gene Factory
- DNA & RNA Synthesis Gene Services | Tsingke
- Gene Synthesis and Cloning Services | Tsingke
- Integrated DNA & RNA Manufacturing Platform | Tsingke Gene Factory
- Отрасль
- Пищевые ингредиенты, Промышленная химия
- Темы
- Синтез генов, секвенирование и биоинструменты, Платформы синтетической биологии и биопроизводство, Дрожжи, ферментация и пищевые ингредиенты
- Роль
- Производитель — “…Its core platform, the Gene Factory, utilizes proprietary automated synthesizers, in-house reagents, and AI-dr…”
Биорешения, которые поставляет 0
Пока не указана поставщиком в решениях с доказательствами.
Что предлагают
Компания не публикует продукты и услуги — узнаем через знакомство.
Новости и статус 6
- 2026 Последний статус: В 2026 г. акции компании размещены на NEEQ. ↗ ↗ ↗
- 2026-04-15 Tsingke Unveils 'Zero-Contact' Gene Synthesis to Safeguard Core Genetic SequencesTsingke Biotech is promoting a security-first approach to gene synthesis with its new “Zero-Contact Sequences” system, an on-site, fully automated platform designed to minimize exposure of core genetic sequences and protect intellectual property. The company …
- 2026-09-22 Tsingke Enables High-Throughput Validation of AI-Designed Proteins and AntibodiesTsingke Biotechnology has launched an integrated high-throughput workflow to experimentally validate large libraries of AI-designed proteins and antibodies, combining gene synthesis, parallel expression, screening, and quantitative binding analysis to …
- 2026-01-20 Tsingke Biotech Launches New Website to Streamline Global Biotech R&D and Translational ServicesTsingke Biotech announces the launch of a redesigned global website featuring a "Gene Factory" model to streamline end-to-end DNA/RNA manufacturing and biotech R&D services, highlighting integrated capabilities across molecular biology, gene therapy, …
- 2026-06-30 Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics – HK BusinesswireTsingke Biotech positions itself as a leading innovator in small nucleic acid therapeutics, offering an integrated platform for siRNA/ASO development, GMP-grade production, and AI-assisted optimization, while emphasizing collaboration across academia, …
- 2026-07-08 Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026 - Thailand Business NewsTsingke showcased AI-assisted discovery of highly selective CLDN18.2 antibodies at AIS 2026, highlighting an AI-enabled workflow to reduce cross-reactivity and its end-to-end antibody development platform (discovery, engineering, and protein expression).
- 2026-03-10 Tsingke Biotech and iGeneTech Forge Strategic Partnership to Lead Synthetic Biology Advancements - Beijing Tsingke Biotech Co., Ltd.Tsingke Biotech is expanding its capabilities through a strategic partnership with iGeneTech to advance synthetic biology. The collaboration signals a focus on leadership in the synthetic biology field and ongoing growth through alliances.
Связи: владельцы, партнёры, аналоги
Владельцы и инвесторы 1
| материнская | Ma Shijin |
Партнёры и сделки 1
| сотрудничество | GeneTech …ustomers globally. Recent developments include the launch of a redesigned global website, strategic partnerships with firms like iGeneTech, and the expansion of its small nucleic acid therapeutic …… |
Похожие компании
Bioserve - A REPROCELL Company · Aurisco Pharmaceutical Co.,Ltd · YXgene · GenePharma · Pepmic Co., Ltd · Dr. KPC Life Sciences Pvt. Ltd. · Synbio Technologies · GENCEFE BIOTECH
Реквизиты и контакты
Контакты, руководители и юридические данные доступны участникам.
Войти как участник